Phase 3 ARCHES Trial Shows XTANDI (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate...
NEW YORK & TOKYO--(BUSINESS WIRE)--Feb 11, 2019--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today…
